Key Documents

View All Documentation

365629

(S,S)-(+)-Tetrandrine

Name: (<I>S</I>,<I>S</I>)-(+)-Tetrandrine
Brand: ALDRICH

98%

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₃₈H₄₂N₂O₆

CAS Number:

518-34-3

Molecular Weight:

622.75

PubChem Substance ID:

24862548

UNSPSC Code:

12352200

MDL number:

MFCD08689909

Beilstein/REAXYS Number:

877811

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

assay

98%

optical activity

[α]20/D +285°, c = 1 in chloroform

mp

219-222 °C (lit.)

SMILES string

COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34

Description

pictograms

GHS06

signalword

Danger

hcodes

H300

pcodes

P264 - P270 - P301 + P310 - P405 - P501

Hazard Classifications

Acute Tox. 2 Oral

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Tetrandrine enhances cytotoxicity of cisplatin in human drug-resistant esophageal squamous carcinoma cells by inhibition of multidrug resistance-associated protein 1.

Tian Hu Wang et al.

Oncology reports, 28(5), 1681-1686 (2012-09-04)

Multidrug resistance is one of the major causes limiting the efficacy of chemotherapeutic agents to control esophageal cancer. Herein, we investigated that the effect and mechanism of tetrandrine (TET) in the human esophageal squamous carcinoma cisplatin-resistant cell line YES-2/DDP. The

Partial synthesis and biological evaluation of bisbenzylisoquinoline alkaloids derivatives: potential modulators of multidrug resistance in cancer.

Ping He et al.

Journal of Asian natural products research, 14(6), 564-576 (2012-05-17)

A series of new bisbenzylisoquinoline alkaloids was partially synthesized from tetrandrine and fangchinoline and evaluated for their ability to reverse P-glycoprotein-mediated multidrug resistance (MDR) in cancer cells. All the test compounds increased the intracellular accumulation rate of rhodamine 123 in

Tetrandrine prevents bone loss in sciatic-neurectomized mice and inhibits receptor activator of nuclear factor κB ligand-induced osteoclast differentiation.

Tatsuo Takahashi et al.

Biological & pharmaceutical bulletin, 35(10), 1765-1774 (2012-10-06)

One of the mediators of osteoclast differentiation is receptor activator of nuclear factor κB ligand (RANKL), which is produced by osteoblasts. Binding of RANKL to its receptor, RANK, activates several signaling pathways, including those involving mitogen-activated protein kinases (MAPKs), nuclear

View All Related Papers